Serum Inflammatory Biomarkers To Discriminate The Cervical Squamous Intraepithelial Lesions

Abstract

Objectives: The aim of this study was to evaluate the relationship between platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), serum, systemic immune-inflammation index (SII), and cervical squamous intraepithelial pathologies Material and methods: The database of our institution was reviewed. Cases with cervical pathology including high grade squamous intraepithelial lesion (HSIL), and low grade squamous intraepithelial lesion (LSIL), between January 2024 to December 2024, were collected. Their CBC results and clinicopathologic data were determined. The relation between the NLR, PLR, MLR, SII, and cervical pathologies was evaluated. Results: There was no statistically significant difference between NLR, PLR, MLR, and cervical squamous intraepithelial lesions, However, SII values were determined significantly higher in patients with HSIL compared to LSIL cases. SII cut-off value was determined to be 845.10 to discriminate HSIL from LSIL. Conclusion: SII seems to be an effective, simple, and promising marker to discriminate HSIL from LSIL in cervical squamous intraepithelial lesions by contrast with widely known simple markers such as NLR, PLR, and MLR.

Keywords

• Neutrophil to lymphocyte ratio
• platelet to lymphocyte ratio
• systemic immune-inflammation index
• cervical squamous intraepithelial pathologies

Serum Inflammatory Biomarkers To Discriminate The Cervical Squamous Intraepithelial Lesions

Abstract

Amaç: Bu çalışmanın amacı, trombosit/lenfosit oranı (PLR), nötrofil/lenfosit oranı (NLR), monosit/lenfosit oranı (MLR), serum, sistemik immün-inflamasyon indeksi (Sİİ) ve servikal skuamöz intraepitelyal patolojiler arasındaki ilişkiyi değerlendirmektir. Gereç ve yöntemler: Kurumumuzun veri tabanı tarandı. Ocak 2024 ile Aralık 2024 tarihleri ​​arasında yüksek dereceli skuamöz intraepitelyal lezyon (HSIL) ve düşük dereceli skuamöz intraepitelyal lezyon (LSIL) dahil olmak üzere servikal patolojisi olan vakalar toplandı. Tam kan sayımı sonuçları ve klinikopatolojik verileri belirlendi. NLR, PLR, MLR, SII ve servikal patolojiler arasındaki ilişki değerlendirildi. Bulgular: NLR, PLR, MLR ve servikal skuamöz intraepitelyal lezyonlar arasında istatistiksel olarak anlamlı bir fark bulunmamıştır. Ancak, SII değerleri HSIL'li hastalarda LSIL vakalarına kıyasla anlamlı derecede yüksek bulunmuştur. HSIL'i LSIL'den ayırt etmek için SII kesme değeri 845.10 olarak belirlenmiştir. Sonuç: SII, NLR, PLR ve MLR gibi yaygın olarak bilinen basit belirteçlerin aksine, servikal skuamöz intraepitelyal lezyonlarda HSIL'i LSIL'den ayırt etmede etkili, basit ve umut verici bir belirteç gibi görünmektedir.

Keywords

• Nötrofil/lenfosit oranı
• trombosit/lenfosit oranı
• sistemik immün-inflamasyon indeksi
• servikal skuamöz intraepitelyal patolojiler

References

1. Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020;32(6):720–8.
2. Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical Cancer Screening: A Review. JAMA. 2023;330(6):547–58.
3. Kakotkin V V, Semina E V, Zadorkina TG, Agapov MA. Prevention Strategies and Early Diagnosis of Cervical Cancer: Current State and Prospects. Diagnostics (Basel, Switzerland). 2023 Feb;13(4).
4. Basoya S, Anjankar A. Cervical Cancer: Early Detection and Prevention in Reproductive Age Group. Cureus. 2022;14(11):e31312.
5. Stuebs FA, Schulmeyer CE, Mehlhorn G, Gass P, Kehl S, Renner SK, et al. Accuracy of colposcopy-directed biopsy in detecting early cervical neoplasia: a retrospective study. Arch Gynecol Obstet. 2019;299(2):525–32.
6. Kaljouw S, Jansen EEL, Aitken CA, Harrijvan LM, Naber SK, de Kok IMCM. Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study. Gynecol Oncol. 2021;160(3):713–20.
7. Zhang YX, Shen ZY, Jia YC, Guo X, Guo XS, Xing Y, et al. The Association of the Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio and Systemic Inflammation Response Index with Short-Term Functional Outcome in Patients with Acute Ischemic Stroke. J Inflamm Res. 2023;16:3619–30.
8. Wang RH, Wen WX, Jiang ZP, Du ZP, Ma ZH, Lu AL, et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients w. Front Immunol. 2023;14:1115031.

9. Ilgen O, Kurt S, Yuzuguldu RI, Ada O, Mankan A. Platelet to lymphocyte and neutrophil to lymphocyte ratios in endometrial pathologies. Ginekol Pol. 2023;94(4):269–74.
10. Ramesh SK, Swain SK, Munikrishnan V, Jameel JKA. Can the Inflammatory Cell Ratio NLR and PLR be Used as a Reliable Marker in Colon Cancer? A Prospective Study. Euroasian J hepato-gastroenterology. 2023;13(2):61–5.
11. Ni L, Tao J, Xu J, Yuan X, Long Y, Yu N, et al. Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020;301(1):251–61.
12. Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, et al. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Ann Surg Oncol. 2020;27(3):898–906.
13. Demircan NC, Atcı MM, Demir M, Işık S, Akagündüz B. Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy. Asia Pac J Clin Oncol. 2023;19(1):104–12.
14. Uzunoglu H, Kaya S. Does systemic immune inflammation index have predictive value in gastric cancer prognosis? North Clin Istanbul. 2023;10(1):24–32.
15. Fest J, Ruiter R, Mulder M, Groot Koerkamp B, Ikram MA, Stricker BH, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer-A population-based cohort study. Int J cancer. 2020;146(3):692–8.
16. Jimbo H, Horimoto Y, Ishizuka Y, Nogami N, Shikanai A, Saito M, et al. Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast Cancer Res Treat. 2022;196(2):291–8.
17. Liao K, Zhang X, Liu J, Teng F, He Y, Cheng J, et al. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy. MedComm. 2023;4(5):e350.
18. Dutta A, Bhagat S, Paul S, Katz JP, Sengupta D, Bhargava D. Neutrophils in Cancer and Potential Therapeutic Strategies Using Neutrophil-Derived Exosomes. Vaccines. 2023;11(6).
19. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863–8.
20. Yıldız HA, Değer MD, Aslan G. Prognostic value of preoperative inflammation markers in non-muscle invasive bladder cancer. Int J Clin Pract. 2021;75(6):e14118.
21. Yin Y, Zhang Y, Li L, Zhang S, Liu N, Yuan S. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Development of a Nomogram in Breast Cancer Patients. Front Oncol. 2021;11:650980.
22. Şahin F, Aslan AF. Relationship between Inflammatory and Biological Markers and Lung Cancer. J Clin Med. 2018;7(7).
23. Danforth DN. The Role of Chronic Inflammation in the Development of Breast Cancer. Cancers (Basel). 2021;13(15).
24. Saputra HM, Hidayatullah F, Kloping YP, Renaldo J, Chung E, Hakim L. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in penile cancer: A systematic review and meta-analysis. Ann Med Surg. 2022;81:104335.
25. Zhu X, Song H, Chen Y, Han F, Wang Q, Cui Y. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Blood to Distinguish Lung Cancer Patients from Healthy Subjects. Dis Markers. 2020;2020:8844698.
26. Tas M, Yavuz A, Ak M, Ozcelik B. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Discriminating Precancerous Pathologies from Cervical Cancer. J Oncol. 2019;2019:2476082.
27. Karcheva M, Yordanov A, Kostadinov S. An overview of cervical cancer epidemiology and prevention in Bulgaria. Germs. 2020;10(4):322–7.
28. Pimple S, Mishra G. Cancer cervix: Epidemiology and disease burden. Cytojournal. 2022;19:21.
29. Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, et al. Cervical cancer in low and middle-income countries. Oncol Lett. 2020;20(3):2058–74.
30. Alrefai EA, Alhejaili RT, Haddad SA. Human Papillomavirus and Its Association With Cervical Cancer: A Review. Cureus. 2024;16(4):e57432.
31. Eun TJ, Perkins RB. Screening for Cervical Cancer. Med Clin North Am. 2020;104(6):1063–78.
32. Cui C, Chen Z, Luo L, Zeng J, Sun X, Sui L, et al. Value of loop electrosurgical excision procedure conization and imaging for the diagnosis of papillary squamous cell carcinoma of the cervix. Front Oncol. 2023;13:1166818.
33. Li Q, Kaidong L, Tian Z, Diao W, Sun Y, Bai Y, et al. Association of Inflammatory Factors with Cervical Cancer: A Bidirectional Mendelian Randomization. J Inflamm Res. 2024;17:10119–30.
34. Berta DM, Teketelew BB, Chane E, Bayleyegn B, Tamir M, Cherie N, et al. Hematological changes in women with cervical cancer before and after cancer treatment: retrospective cohort study. Sci Rep [Internet]. 2024;14(1):27630. Available from: https://doi.org/10.1038/s41598-024-75937-6
35. Taguchi A, Nakajima Y, Furusawa A, Yoshino Y, Takao M, Kashiyama T, et al. High neutrophil-to-lymphocyte ratio is a predictor of short-term survival for patients with recurrent cervical cancer after radiation-based therapy. J Obstet Gynaecol Res. 2021;47(5):1862–70.
36. Trinh H, Dzul SP, Hyder J, Jang H, Kim S, Flowers J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clin Chim Acta. 2020;510:711–6.
37. Vural S, Muhtaroğlu A, Güngör M. Systemic immune-inflammation index: A new marker in differentiation of different thyroid diseases. Medicine (Baltimore). 2023;102(31):e34596.
38. Gao Y, Guo W, Cai S, Zhang F, Shao F, Zhang G, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer. 2019;10(14):3188–96.
39. Holub K, Biete A. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2019;21(7):836–44.
40. Zhu M, Feng M, He F, Han B, Ma K, Zeng X, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer. Clin Chim Acta. 2018;483:296–302.
41. Hajizadeh N, Baghestani AR, Pourhoseingholi MA, Khadem Maboudi AA, Farzaneh F, Faghih N. Evaluation of the Factors Affecting the Cure Rate of Cervical Intra-Epithelial Neoplasia Recurrence Using Defective Models. J Res Health Sci. 2021;21(3):e00524.
42. Origoni M, Cantatore F, Candotti G, Candiani M. Prognostic Significance of Neutrophil/Lymphocytes Ratio (NLR) in Predicting Recurrence of Cervical Dysplasia. Biomed Res Int. 2022;2022:1149789.
43. Xu L, Song J. Elevated neutrophil-lymphocyte ratio can be a biomarker for predicting the development of cervical intraepithelial neoplasia. Medicine (Baltimore). 2021;100(28):e26335.
44. Li YX, Chang JY, He MY, Wang HR, Luo DQ, Li FH, et al. Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer. J Oncol. 2021;2021:2939162.
45. Tóth Z, Lőczi L, Sebők B, Merkely P, Keszthelyi E, Lintner B, et al. Neutrophil/Lymphocyte Ratio (NLR) as a Predictive Marker for p16 Positivity and Cervical Cancer Progression: Insights from the SCOPE Study. Cancers (Basel). 2025;17(6).
46. Zou P, Yang E, Li Z. Neutrophil-to-lymphocyte ratio is an independent predictor for survival outcomes in cervical cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):21917.
47. Alrajjal A, Pansare V, Choudhury MSR, Khan MYA, Shidham VB. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. Cytojournal. 2021;18:16.
48. Neumeyer S, Tanaka LF, Liang LA, Klug SJ. Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data. Cancer Med. 2023;12(16):17284–95.
49. Preston M, Richards A. Risk of High-Grade Cervical Dysplasia in Older Patients With a Positive Human Papillomavirus Cervical Screening Test. J Low Genit Tract Dis. 2025;29(1):55–9.